NCT07218926 2026-01-30A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKlinePhase 3 Recruiting450 enrolled
NCT05489237 2025-11-17First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsIDRx Inc. - A GSK CompanyPhase 1 Recruiting278 enrolled